Teva Pharmaceutical Industries Ltd.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2016 | $3.89B | $2.99B | $901.0M | $124.0M |
| FY2017 | $2.23B | $1.35B | $874.0M | $133.0M |
| FY2018 | $2.45B | $1.80B | $651.0M | $155.0M |
| FY2019 | $748.0M | $223.0M | $525.0M | $119.0M |
| FY2020 | $1.22B | $638.0M | $578.0M | $129.0M |
| FY2021 | $798.0M | $236.0M | $562.0M | $119.0M |
| FY2022 | $1.59B | $1.04B | $548.0M | $124.0M |
| FY2023 | $1.37B | $842.0M | $526.0M | $121.0M |
| FY2024 | $1.25B | $749.0M | $498.0M | $123.0M |
| FY2025 | $1.65B | $1.15B | $501.0M | $157.0M |